Monthly research recap
Ayahuasca research: October 2026
What October 2026's 11 new studies found, synthesized from the papers below. All Ayahuasca research →
The synthesis
Synthesized from 11 studies in the library · AI-generated, grounded in the abstracts below
Found by searching the library for Ayahuasca, yage, hoasca, banisteriopsis, then ranked by relevance.
Research indexed to October 2026 on ayahuasca is mostly preclinical, observational, and policy-oriented rather than definitive clinical evidence. The one double-blind RCT found no persistent cognitive harm from a single dose, while animal studies suggest possible fear-memory and binge-eating effects and observational work documents transient speech and language changes after ceremonies. Overall the findings are preliminary and inconsistent in scope, with small samples, short follow-up, and little replication.
Evidence by study
Direction is which way each study's own result points, not our rating of the study.
What the directions mean
- Supports:
- the study found the intervention worked, or its hypothesis held.
- Opposes:
- it found the opposite, no benefit or a harm.
- No effect:
- no significant difference either way.
- Mixed:
- effects in both directions within the same study.
- Unclear:
- the abstract does not report a direction.
| Study | Design | Sample size | Direction | Finding |
|---|---|---|---|---|
| Independent evolution of harmala alkaloids in medicinal Syrian rue and ayahuasca plants 2026 | theoretical/genomic | Supports | Argues that Syrian rue and the ayahuasca vine independently evolved harmala alkaloid biosynthesis through convergent enzyme, pathway, and genome changes. | |
| Psychedelics and psychosis: A systematic review of recent-era studies (1984-2025). 2026 | systematic review | Mixed | Population and controlled-trial data showed no consistent link between lifetime psychedelic use and psychosis, with minimal risk in supervised settings, while case reports and emergency data showed higher rates, especially with personal or family psychiatric history and unsupervised use. | |
| Behavioral Shifts in Natural Speech, Language, and Facial Expression Following Ayahuasca Ceremonies 2026 | observational ecological momentary assessment | 15 | Supports | Language content, structure, sentiment, and word count changed after ayahuasca ceremonies, with minor effects on head movement, and the changes waned over the following week. |
| Evaluation of the Effects of Different Doses of Ayahuasca on Intelligence and Verbal Memory in Healthy Volunteers 2026 | double-blind RCT | 28 | No effect | A single ayahuasca dose produced no significant or persistent changes in intelligence or verbal memory versus placebo, with only better delayed recall in the placebo group at 4 hours and no effects at 21 days. |
| Comparative chromosome-scale genomics of the ayahuasca liana Banisteriopsis caapi reveals paleopolyploid ancestry and recent tandem-gene expansions as candidate signatures of ethnovariety differentiation 2026 | genomic study | Unclear | The two ethnovarieties differ mainly through localized genomic remodeling, repeat turnover, and tandem-gene expansions rather than wholesale gene-content divergence, with about 78% repetitive DNA. | |
| Who seeks ayahuasca and why? Participant profiles and engagement patterns in a community-based practice (2014-2026) 2026 | retrospective observational | 1134 | Supports | Participants were mostly stable middle-aged adults seeking personal growth rather than symptom relief, with high life satisfaction and low current psychological disorder, and most attended only occasionally without escalating involvement. |
| Uso inadecuado de la ayahuasca y sus impactos en la salud: percepción de consumidores 2026 | quantitative descriptive survey | Mixed | Consumers reported physical risks such as severe nausea, vomiting, and increased blood pressure and psychological risks such as traumatic memories, post-ceremony depression, anxiety, and psychosis, and valued prior information, medical evaluation, and regulation. | |
| Salud intercultural en Pastaza: regulación del uso de plantas medicinales y de la ayahuasca 2026 | review | Unclear | Argues that constitutional recognition of ancestral medicine in Pastaza lacks specific safety, dosing, and knowledge-protection criteria, and that ayahuasca risks stem from decontextualized use, requiring intercultural regulation co-developed with communities. | |
| Ayahuasca Impairs Fear Memory Reconsolidation and Promotes Rapid Structural Plasticity in the Hippocampus and Prelimbic Cortex. 2026 | controlled animal experiment | Supports | Ayahuasca at 60 mg/kg around fear memory retrieval reduced freezing, indicating impaired fear memory reconsolidation, and increased dendritic spine density in hippocampal regions and prelimbic cortex without affecting adult hippocampal neurogenesis. | |
| Intercultural pathways to indigenous mental health: the integration of ayahuasca in community care in the Yaqui intercultural medicine clinic in Sonora, Mexico 2026 | community case study | 130 | Supports | Argues that culturally adapted psychedelic-assisted care integrating ayahuasca can be implemented within Indigenous territory when grounded in community ownership and collaboration between Indigenous and biomedical knowledge systems, though constrained by isolation, resources, workforce, and legal uncertainty. |
| Acute ayahuasca administration attenuates binge‐like eating and anxiety‐related behaviors in mice subjected to intermittent fasting 2026 | preclinical animal study | Supports | A single ayahuasca dose (1.76 mg/kg DMT) selectively reduced food and sucrose intake in the first hour of refeeding, reversed anxiety-like behavior, and increased hypothalamic CART expression in mice on a binge-like eating protocol. |
Points of agreement
- Ayahuasca is being studied across preclinical, clinical, observational, genomic, and policy domains rather than through a single dominant design.
- Supervised or controlled settings are repeatedly described as lower-risk than unsupervised or decontextualized use.
- Several lines of work point to acute or short-lived biobehavioral effects rather than persistent changes.
Conflicts
- Observational and case-report data raise psychosis and psychological risk concerns, while population and controlled-trial data show minimal risk.
- Observational reports of cognitive benefits in experienced users contrast with the RCT finding of no cognitive enhancement or persistent impairment.
- Animal findings of therapeutic-like effects have no direct clinical confirmation in these studies.
Gaps
- Durability of effects beyond days to weeks is largely untested.
- Clinical samples are small and preliminary, limiting statistical power.
- Blinding integrity and expectancy effects in ayahuasca trials are not addressed.
- Most clinical and observational data come from specific cultural or community settings, limiting generalizability.
- Dose-response relationships are examined in only one small trial.
- Long-term safety data, especially psychiatric risk, remain limited.